Sunshine Biopharma Net Worth
Sunshine Biopharma Net Worth Breakdown | SBFM |
Sunshine Biopharma Net Worth Analysis
Sunshine Biopharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sunshine Biopharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sunshine Biopharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sunshine Biopharma's net worth analysis. One common approach is to calculate Sunshine Biopharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sunshine Biopharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sunshine Biopharma's net worth. This approach calculates the present value of Sunshine Biopharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sunshine Biopharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sunshine Biopharma's net worth. This involves comparing Sunshine Biopharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sunshine Biopharma's net worth relative to its peers.
To determine if Sunshine Biopharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sunshine Biopharma's net worth research are outlined below:
| Sunshine Biopharma generated a negative expected return over the last 90 days | |
| Sunshine Biopharma has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 10.14 M. | |
| Sunshine Biopharma currently holds about 41.74 M in cash with (8.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.21. | |
| Sunshine Biopharma has a poor financial position based on the latest SEC disclosures |
Sunshine Biopharma Quarterly Good Will |
|
Sunshine Biopharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sunshine Biopharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sunshine Biopharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 2nd of April 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Sunshine Biopharma Target Price Consensus
Sunshine target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Sunshine Biopharma's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Sunshine analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Sunshine stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Sunshine Biopharma, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSunshine Biopharma Target Price Projection
Sunshine Biopharma's current and average target prices are 2.29 and 300.00, respectively. The current price of Sunshine Biopharma is the price at which Sunshine Biopharma is currently trading. On the other hand, Sunshine Biopharma's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Sunshine Biopharma Market Quote on 1st of March 2025
Target Price
Analyst Consensus On Sunshine Biopharma Target Price
Know Sunshine Biopharma's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sunshine Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sunshine Biopharma backward and forwards among themselves. Sunshine Biopharma's institutional investor refers to the entity that pools money to purchase Sunshine Biopharma's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | |||
| Main Street Group Ltd | 2024-09-30 | 0.0 | |
| Nordwand Advisors Llc | 2024-12-31 | 0.0 | |
| Connective Capital Management Llc | 2024-12-31 | 11.3 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 7.6 K | |
| Ubs Group Ag | 2024-12-31 | 868 | |
| Sbi Securities Co Ltd | 2024-12-31 | 709 | |
| Bank Of America Corp | 2024-12-31 | 5.0 | |
| Northwestern Mutual Wealth Management Co | 2024-12-31 | 4.0 | |
| Jaffetilchin Investment Partners, Llc | 2024-09-30 | 1.0 | |
| Td Waterhouse Canada Inc | 2024-09-30 | 1.0 | |
| Federation Des Caisses Desjardins Du Quebec | 2024-09-30 | 1.0 |
Follow Sunshine Biopharma's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 6.2 M.Market Cap |
|
Project Sunshine Biopharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.16) | |
| Return On Capital Employed | (0.20) | (0.19) | |
| Return On Assets | (0.15) | (0.16) | |
| Return On Equity | (0.24) | (0.23) |
When accessing Sunshine Biopharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sunshine Biopharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sunshine Biopharma's profitability and make more informed investment decisions.
Evaluate Sunshine Biopharma's management efficiency
Sunshine Biopharma has return on total asset (ROA) of (0.1075) % which means that it has lost $0.1075 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1798) %, meaning that it created substantial loss on money invested by shareholders. Sunshine Biopharma's management efficiency ratios could be used to measure how well Sunshine Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 1st of March 2025, Return On Tangible Assets is likely to grow to -0.16. In addition to that, Return On Capital Employed is likely to grow to -0.19. At this time, Sunshine Biopharma's Intangible Assets are very stable compared to the past year. As of the 1st of March 2025, Fixed Asset Turnover is likely to grow to 22.48, though Return On Tangible Assets are likely to grow to (0.16).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.6 K | 1.6 K | |
| Tangible Book Value Per Share | 1.5 K | 1.5 K | |
| Enterprise Value Over EBITDA | 2.12 | 2.23 | |
| Price Book Value Ratio | 0.36 | 0.34 | |
| Enterprise Value Multiple | 2.12 | 2.23 | |
| Price Fair Value | 0.36 | 0.34 |
The strategic decisions made by Sunshine Biopharma management significantly impact its financial stability and market performance. Evaluating these factors helps determine whether the stock is a worthwhile investment.
Enterprise Value Revenue 39.4772 | Revenue | Quarterly Revenue Growth 0.416 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sunshine Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sunshine Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sunshine Biopharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Steve Slilaty over a month ago Disposition of 2591500 shares by Steve Slilaty of Sunshine Biopharma at 0.05 subject to Rule 16b-3 | ||
Michel Roy over a month ago Insider Trading | ||
Keller Andrew Mark over two months ago Disposition of tradable shares by Keller Andrew Mark of Sunshine Biopharma subject to Rule 16b-3 | ||
Camille Sebaaly over six months ago Acquisition by Camille Sebaaly of 14000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Camille Sebaaly over six months ago Acquisition by Camille Sebaaly of 26000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Abderrazzak Merzouki over six months ago Acquisition by Abderrazzak Merzouki of 27000000 shares of Sunshine Biopharma at 0.001 subject to Rule 16b-3 | ||
Steve Slilaty over six months ago Discretionary transaction by Steve Slilaty of 17000000 shares of Sunshine Biopharma subject to Rule 16b-3 | ||
Steve Slilaty over a year ago Acquisition or disposition of Sunshine Biopharma securities by Steve Slilaty |
Sunshine Biopharma Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
F3 | 21st of January 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
8K | 15th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 6th of January 2025 Other Reports | ViewVerify |
Sunshine Biopharma Earnings Estimation Breakdown
The calculation of Sunshine Biopharma's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Sunshine Biopharma is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Sunshine Biopharma is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Sunshine Biopharma Earnings Projection Consensus
Suppose the current estimates of Sunshine Biopharma's value are higher than the current market price of the Sunshine Biopharma stock. In this case, investors may conclude that Sunshine Biopharma is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Sunshine Biopharma's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 1 | 50.0% | -0.94 | 0.0 | -127.9 |
Sunshine Biopharma Earnings per Share Projection vs Actual
Actual Earning per Share of Sunshine Biopharma refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Sunshine Biopharma predict the company's earnings will be in the future. The higher the earnings per share of Sunshine Biopharma, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Sunshine Biopharma Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Sunshine Biopharma, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Sunshine Biopharma should always be considered in relation to other companies to make a more educated investment decision.Sunshine Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Sunshine Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-11 | 2024-09-30 | 9 | -0.94 | -9.94 | 110 | ||
2024-08-16 | 2024-06-30 | -7.4 | -9.94 | -2.54 | 34 | ||
2024-05-20 | 2024-03-31 | -1.04 | -2.0 | -0.96 | 92 | ||
2024-03-28 | 2023-12-31 | -3 | -5.0 | -2.0 | 66 | ||
2023-11-13 | 2023-09-30 | -0.06 | -0.04 | 0.02 | 33 | ||
2023-08-14 | 2023-06-30 | -0.08 | -0.02 | 0.06 | 75 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sunshine Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in Sunshine Stock, please use our How to Invest in Sunshine Biopharma guide.You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sunshine Biopharma. If investors know Sunshine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sunshine Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (127.90) | Revenue Per Share | Quarterly Revenue Growth 0.416 | Return On Assets | Return On Equity |
The market value of Sunshine Biopharma is measured differently than its book value, which is the value of Sunshine that is recorded on the company's balance sheet. Investors also form their own opinion of Sunshine Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Sunshine Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sunshine Biopharma's market value can be influenced by many factors that don't directly affect Sunshine Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sunshine Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sunshine Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sunshine Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.